Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation - PubMed
a day ago
- #PPARα Pathway
- #Liver Disease
- #Traditional Chinese Medicine
- Lianhe Xiaozhi ointment (LXO) is derived from Huanglian Wendan decoction and has a national invention patent.
- LXO is recognized for treating metabolic disorders, especially metabolic dysfunction-associated steatotic liver disease (MASLD).
- Six key bioactive components in LXO contribute to its efficacy against MASLD.
- LXO provides multiple therapeutic effects: weight gain control, improved glucose/lipid metabolism, reduced liver injury, and gut microbiota correction.
- LXO activates the peroxisome proliferator-activated receptor alpha (PPARα) pathway, crucial for its lipid-lowering effects.
- In vitro studies confirm that PPARα antagonist reduces LXO's lipid-lowering capacity.
- LXO's therapeutic benefits for MASLD are partly due to PPARα pathway activation.